Different sources of MSCs on pulmonary fibrosis in C57BL/6 mice

Biocell

article

SHUCAI WU¹  DENGRUI LI¹  SUMIN GUO¹  LI GAO²  YONGHUI YANG¹ 

[1] The Center of Lung Cancer Prevention, Hebei Province Chest Hospital;College of Life Science, Hebei Normal University

关键词: Pulmonary fibrosis;    Umbilical cord blood;    Umbilical cord placenta;    Mesenchymal stem cells;    C57BL/6 mice IκB-α;   

DOI  :  10.32604/biocell.2021.011379

学科分类：仪器

来源: Biocell

【 摘 要 】

Since stem cell therapy is the most effective treatment in the field of tissue reparation and reconstitution, the present study aimed to explore the different sources of mesenchymal stem cells (MSCs) on the different effects of pulmonary fibrosis-related cytokines in C57BL/6 mice. For reaching this goal, we isolated MSCs from umbilical cord blood and placenta and used for stem cell therapy in a mouse model of pulmonary fibrosis model. The pulmonary fibrosis model was done by injecting bleomycin into the trachea of C57BL/6 mice. Then we assessed the degree of pulmonary fibrosis in each mouse lung tissue at weeks 1, 2, 3, and 4. In addition, flow cytometry was used to evaluate the frequency of CD73, CD90, CD106, CD34, CD45, CD14 cells at the mononuclear cell level; and western blotting assays revealed the expression of IκB-α. Our results showed that stem cell therapy by placenta-derived MSC had a lower level of CD34, CD45, CD14 cells at the mononuclear cell level, and that improved pulmonary fibrosis at both molecular and pathological levels. In addition, western blotting assays revealed that the expression of IκB-α was down-regulated in MSC-treated animals. In addition, placenta-derived MSC was the most effective in improving pulmonary fibrosis in comparison to other sources. This study suggests that MSC might be a novel therapeutic approach in pulmonary fibrosis due to an enhanced anti-inflammatory effect. Also, MSC modification by gene editing could enhance their therapeutic effect in mouse pulmonary fibrosis.

【 授权许可】

CC BY